跳至主要内容
临床试验/EUCTR2007-000357-54-FR
EUCTR2007-000357-54-FR进行中(未招募)不适用

Chemotherapy of first line reinforced for cancers of the colonist and the rectum with hepatic and/or pulmonary metastases potentially résécables: Strong association FOLFIRI and ERBITUX - ERBIFORT

niversityHospitalGrenoble0 个研究点开始时间: 2007年6月20日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Will be proposed for the study the subjects answering each following criterion: Index of performance WHO 18 years
  • Rectal Adenocarcinomist colic or with hepatic metastases (synchronous or métachrones) not résécables of start: - Less than 8 hepatic metastases and less than 6 hepatic segments reached - Not more than 2 extra-hepatic metastatic sites potentially résécables
  • Visceral metastases potentially résécables if tumoral regression after chemotherapy
  • Cancer (primitive and/or metastases) histologically proven
  • Immediate Non-resecability reserve by a hépato-biliary surgeon at a multidisciplinary conciliation meeting
  • At least a measurable supra-centimetric metastasis by helicoid tomodensitometry and/or IRM
  • Life expectancy 3 months
  • Bilirubine 1500/mm3, plates 100 000/mm3
  • Creatinin 60 ml/min
  • Rate of Prothrombine 70 %
  • Enlightened assent
  • Possible follow-up
  • Nobody affiliated with the social security or profit of such a mode
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • could not be included the subjects answering at least one of the following criteria:
  • More than 6 hepatic segments reached of metastases
  • More than 2 extra-hepatic metastatic sites or not obvious resecability of extra-hepatic metastases
  • Cerebral metastases or carcinomatous meningitis of cancer colorectal
  • Carcinose péritonéale or c?liaque ganglionic extension
  • Osseous metastases?
  • Antecedents of another malignant tumour (except cutaneous cancers basocellulaires or in situ cancers of the uterine collar)
  • Co-morbidity considered to be too important or contra-indicating chemotherapy (or the surgical résection of metastases (for example: angor unstable, symptomatic cardiac insufficiency)
  • Pregnant woman parturient, mother who nurses
  • Antecedents of anti-cancer chemotherapy (except an auxiliary chemotherapy if it has been finished for at least 3 months)Inclusion in another therapeutic test requiring the realization of other treatments that those of this study
  • Nobody private of freedom by court order or administrative, anybody being the subject of a legal protection measure,

研究者

发起方
niversityHospitalGrenoble

相似试验